121 related articles for article (PubMed ID: 27571355)
1. Structure of the Epigenetic Oncogene MMSET and Inhibition by N-Alkyl Sinefungin Derivatives.
Tisi D; Chiarparin E; Tamanini E; Pathuri P; Coyle JE; Hold A; Holding FP; Amin N; Martin AC; Rich SJ; Berdini V; Yon J; Acklam P; Burke R; Drouin L; Harmer JE; Jeganathan F; van Montfort RL; Newbatt Y; Tortorici M; Westlake M; Wood A; Hoelder S; Heightman TD
ACS Chem Biol; 2016 Nov; 11(11):3093-3105. PubMed ID: 27571355
[TBL] [Abstract][Full Text] [Related]
2. Cancers and the NSD family of histone lysine methyltransferases.
Morishita M; di Luccio E
Biochim Biophys Acta; 2011 Dec; 1816(2):158-63. PubMed ID: 21664949
[TBL] [Abstract][Full Text] [Related]
3. Identification of LEM-14 inhibitor of the oncoprotein NSD2.
Shen Y; Morishita M; Lee D; Kim S; Lee T; Mevius DEHF; Roh Y; di Luccio E
Biochem Biophys Res Commun; 2019 Jan; 508(1):102-108. PubMed ID: 30471851
[TBL] [Abstract][Full Text] [Related]
4. In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L.
Morishita M; Mevius D; di Luccio E
BMC Struct Biol; 2014 Dec; 14():25. PubMed ID: 25494638
[TBL] [Abstract][Full Text] [Related]
5. NMR backbone resonance assignment and solution secondary structure determination of human NSD1 and NSD2.
Amin N; Nietlispach D; Qamar S; Coyle J; Chiarparin E; Williams G
Biomol NMR Assign; 2016 Oct; 10(2):315-20. PubMed ID: 27356987
[TBL] [Abstract][Full Text] [Related]
6. High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2.
Coussens NP; Kales SC; Henderson MJ; Lee OW; Horiuchi KY; Wang Y; Chen Q; Kuznetsova E; Wu J; Chakka S; Cheff DM; Cheng KC; Shinn P; Brimacombe KR; Shen M; Simeonov A; Lal-Nag M; Ma H; Jadhav A; Hall MD
J Biol Chem; 2018 Aug; 293(35):13750-13765. PubMed ID: 29945974
[TBL] [Abstract][Full Text] [Related]
7. The NSD family of protein methyltransferases in human cancer.
Vougiouklakis T; Hamamoto R; Nakamura Y; Saloura V
Epigenomics; 2015 Aug; 7(5):863-74. PubMed ID: 25942451
[TBL] [Abstract][Full Text] [Related]
8. NSD2 as a Promising Target in Hematological Disorders.
Azagra A; Cobaleda C
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232375
[TBL] [Abstract][Full Text] [Related]
9. Identification of a peptide inhibitor for the histone methyltransferase WHSC1.
Morrison MJ; Boriack-Sjodin PA; Swinger KK; Wigle TJ; Sadalge D; Kuntz KW; Scott MP; Janzen WP; Chesworth R; Duncan KW; Harvey DM; Lampe JW; Mitchell LH; Copeland RA
PLoS One; 2018; 13(5):e0197082. PubMed ID: 29742153
[TBL] [Abstract][Full Text] [Related]
10. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells.
Martinez-Garcia E; Popovic R; Min DJ; Sweet SM; Thomas PM; Zamdborg L; Heffner A; Will C; Lamy L; Staudt LM; Levens DL; Kelleher NL; Licht JD
Blood; 2011 Jan; 117(1):211-20. PubMed ID: 20974671
[TBL] [Abstract][Full Text] [Related]
11. Structural insights into the regulation and the recognition of histone marks by the SET domain of NSD1.
Morishita M; di Luccio E
Biochem Biophys Res Commun; 2011 Aug; 412(2):214-9. PubMed ID: 21806967
[TBL] [Abstract][Full Text] [Related]
12. The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.
Bennett RL; Swaroop A; Troche C; Licht JD
Cold Spring Harb Perspect Med; 2017 Jun; 7(6):. PubMed ID: 28193767
[TBL] [Abstract][Full Text] [Related]
13. Sinefungin derivatives as inhibitors and structure probes of protein lysine methyltransferase SETD2.
Zheng W; Ibáñez G; Wu H; Blum G; Zeng H; Dong A; Li F; Hajian T; Allali-Hassani A; Amaya MF; Siarheyeva A; Yu W; Brown PJ; Schapira M; Vedadi M; Min J; Luo M
J Am Chem Soc; 2012 Oct; 134(43):18004-14. PubMed ID: 23043551
[TBL] [Abstract][Full Text] [Related]
14. NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation.
García-Carpizo V; Sarmentero J; Han B; Graña O; Ruiz-Llorente S; Pisano DG; Serrano M; Brooks HB; Campbell RM; Barrero MJ
Sci Rep; 2016 Sep; 6():32952. PubMed ID: 27604143
[TBL] [Abstract][Full Text] [Related]
15. Metformin Elicits Antitumor Effects and Downregulates the Histone Methyltransferase Multiple Myeloma SET Domain (MMSET) in Prostate Cancer Cells.
White-Al Habeeb NM; Garcia J; Fleshner N; Bapat B
Prostate; 2016 Dec; 76(16):1507-1518. PubMed ID: 27404348
[TBL] [Abstract][Full Text] [Related]
16. MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents.
Shah MY; Martinez-Garcia E; Phillip JM; Chambliss AB; Popovic R; Ezponda T; Small EC; Will C; Phillip MP; Neri P; Bahlis NJ; Wirtz D; Licht JD
Oncogene; 2016 Nov; 35(45):5905-5915. PubMed ID: 27109101
[TBL] [Abstract][Full Text] [Related]
17. The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors.
Hudlebusch HR; Santoni-Rugiu E; Simon R; Ralfkiær E; Rossing HH; Johansen JV; Jørgensen M; Sauter G; Helin K
Clin Cancer Res; 2011 May; 17(9):2919-33. PubMed ID: 21385930
[TBL] [Abstract][Full Text] [Related]
18. The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors.
Topchu I; Pangeni RP; Bychkov I; Miller SA; Izumchenko E; Yu J; Golemis E; Karanicolas J; Boumber Y
Cell Mol Life Sci; 2022 May; 79(6):285. PubMed ID: 35532818
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Small-Molecule Antagonists of the PWWP Domain of NSD2.
Ferreira de Freitas R; Liu Y; Szewczyk MM; Mehta N; Li F; McLeod D; Zepeda-Velázquez C; Dilworth D; Hanley RP; Gibson E; Brown PJ; Al-Awar R; James LI; Arrowsmith CH; Barsyte-Lovejoy D; Min J; Vedadi M; Schapira M; Allali-Hassani A
J Med Chem; 2021 Feb; 64(3):1584-1592. PubMed ID: 33522809
[TBL] [Abstract][Full Text] [Related]
20. MMSET I acts as an oncoprotein and regulates GLO1 expression in t(4;14) multiple myeloma cells.
Xie Z; Chooi JY; Toh SHM; Yang D; Basri NB; Ho YS; Chng WJ
Leukemia; 2019 Mar; 33(3):739-748. PubMed ID: 30470837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
